Cost-Effectiveness of Crizotinib for Second and Third-Line Treatment of Non-Small Cell Lung Cancer in Ecuador
May 1, 2018, 00:00
10.1016/j.jval.2018.04.194
https://www.valueinhealthjournal.com/article/S1098-3015(18)30494-7/fulltext
Title :
Cost-Effectiveness of Crizotinib for Second and Third-Line Treatment of Non-Small Cell Lung Cancer in Ecuador
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30494-7&doi=10.1016/j.jval.2018.04.194
First page :
Section Title :
Open access? :
No
Section Order :
1046